Jefferies starts Nuvalent at buy, cites lung cancer drug candidates [Seeking Alpha]
Nuvalent, Inc. - Class A (NUVL)
NASDAQ:AMEX Investor Relations:
nuvelinc.com/company/investor_relations.html
Company Research
Source: Seeking Alpha
The investment firm sees zidesamtinib, also known as NVL-520, potentially generating adjusted peak sales of around $1.7B in the treatment of ROS1+ NSCLC and NVL-655 with adjusted peak sales of roughly $2.6B for ALK+ NSCLC. The company expects pivotal data on at least one candidate in 2025, with a potential interim data in 2024 and FDA approval 2026. The bank also noted that Nuvalent has around $720M in cash, enough to fund operations into 2027. Jefferies set its price target for the stock at $97. Recommended For You More Trending News Recommended For You More Trending News About NUVL Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
NUVL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVL alerts
High impacting Nuvalent, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
NUVL
News
- Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $97.00 price target on the stock.MarketBeat
- Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024PR Newswire
- Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at Leerink Partnrs from a "market perform" rating to an "outperform" rating.MarketBeat
- Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $110.00 price target on the stock, up previously from $69.00.MarketBeat
- Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth [Yahoo! Finance]Yahoo! Finance
NUVL
Earnings
- 11/14/23 - In-Line
NUVL
Sec Filings
- 5/3/24 - Form 4
- 5/1/24 - Form 4
- 4/26/24 - Form ARS
- NUVL's page on the SEC website